Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Read Why Did Cantor Upgrade Aurora Cannabis Stock

Published 24/06/2022, 14:23
Updated 24/06/2022, 15:11
© Reuters.  Read Why Did Cantor Upgrade Aurora Cannabis Stock

Cantor Fitzgerald has upgraded Aurora Cannabis Inc (NASDAQ: ACB) to Overweight from Neutral with a price target of C$4.05, up from C$3.90. The analyst views Aurora as an attractively valued pure cannabis play.

He expects Europe, specifically Germany, to be a "relevant potential catalyst and sentiment driver" for cannabis stocks over the next 12-18 months.

Only Aurora and Tilray Inc (NASDAQ: TLRY) have licenses to produce in Germany. Cantor believes Tilray and Aurora should be well-positioned on questions regarding imports in the future German recreational market and the limited number of new domestic production licenses issued.

Related: Aurora Cannabis Announces More Layoffs, Here's Why

The analyst is "more comfortable" recommending Aurora over Tilray as a play on Germany and views the selloff as a buying opportunity.

German Market: Cantor estimates the German medical market at about 30 tons, equivalent to €480 million (an average price of €16/gram) that could increase to €1.53 billion in 2028 (€3 billion taking retail prices) with improved quality and increased domestic production.

Flower accounts for 2/3 of sales and extracts for the balance (all reimbursed). There are about 60 suppliers, including importers and wholesalers.

The analyst expects ACB leads the flower segment with a ~15% share. TLRY is #1 in extracts but losing its market share on more potent offerings from competitors.

Price Action: ACB shares are up 4.23% at $1.48 during the premarket session on the last check Friday.

Photo via Wikimedia Commons

Latest Ratings for ACB

Nov 2021Cantor FitzgeraldMaintainsNeutral
Oct 2021Cantor FitzgeraldMaintainsNeutral
Oct 2021Cantor FitzgeraldMaintainsNeutral
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.